A Comparative Study of FDPs and D-dimers in Patients with Breast Cancer

M Z KHAN M TAYYIB T TASNEEM M FAROOQ I D UJJAN N A CHAUDHRY

Department of Pathology, Postgraduate Medical Institute, Lahore.
Correspondence to Dr. Malik Zeb Khan, Demonstrator Pathology, Khyber Teaching Hospital, Peshawar

Seventy Five subjects were selected. Fifty subjects were breast cancer patients and 25 healthy control subjects were included. FDPs and D-dimers were performed by using commercially available kits. Results obtained were analyzed by using chi-square (X^2) test and level of significance was done. A significant increase in the levels of FDPs and D-dimers were found in patients with breast cancer.

Key words: Breast cancer, FDPs, D- dimers

Plasma D-dimers are the specific derivatives of cross-linked fibrin, which are produced when fibrin is degraded by plasmin and concentrations are raised by thrombolytic. Plasma D-dimer represents a significant advance over current and historical FDP assays. Firstly it identifies specifically, the presence of cross-linked fibrin derivatives without interference from fibrinogen and non-cross-linked fibrin, and therefore, identifies intravascular thrombosis and fibrinolysis as distinct from fibrinogenolysis. Because of high specificity of D-dimer, the monoclonal antibody can be used with plasma samples, thereby differentiating fibrinolysis from fibrinogenolysis and conferring an advantage over most standard assays for FDP. D-dimer is the only test that directly addresses both thrombin and plasmin generation i.e. generation of thrombin resulting in a cross-linked fibrin clot and of plasmin resulting in a lysis of a cross-linked fibrin clot. The use of a rapid and sensitive D-dimer test for diagnosis and during the treatment of disseminated intravascular coagulation (DIC) and thrombolytic therapy, may give a better understanding of the formation and dissolution of fibrin in thrombotic disease. Detection of fragment DD, therefore offers a unique advantage over other laboratory tests for DIC, because it addresses both dimensions of DIC.

The D-dimer and FDP tests are very useful for the rapid diagnosis of DIC. Clinically, the relationship between malignancy and thrombosis has been obvious for over 100 years. Thrombo-embolism is present in up to half of cancer patients at autopsy and there is higher incidence of occult malignancy in patients with deep vein thrombosis (DVT). Thrombosis in cancer often is migratory and may involve superficial veins and relatively unusual sites. In the laboratory, evidence of intravascular coagulation is readily obtained. Some have thrombocytopenia, falling fibrinogen levels and raised fibrinogen degradation product (FDP), but these represent only the decompensated form of DIC, and a larger proportion has evidence of compensated or overcompensated DIC. Thrombocytosis is more common, and functional defects such as reduced adhesion, aggregation and clot retraction also may be observed.

Hyperfibrinogenemia is common but acquired dysfibrinogenemia is rare unless the liver is involved. As intravascular activation of coagulation and fibrinolysis occur together, cancer patients may have shortened euglobulin clot lysis times, decreased plasminogen levels and an increase in plasmin-antiplasmin complexes. Most patients with cancer complicated by acute DIC have elevated FDP levels. The likelihood of increased FDP is greater in patients with remote metastases, compared to localized disease and may have prognostic value.

The purpose of the present study is to assess the coagulation abnormalities in patients of breast cancer and to help the clinician in early detection of DIC and management of patients at different stages of breast cancer.

Subjects and Methods

Seventy five subjects were selected and divided into two groups. Group I included 50 breast cancer patients and Group II included 25 normal, healthy controls: 1.8 ml of blood was mixed with 0.2 ml of sodium citrate for fibrinogen and D-dimers. 2 ml of blood was transferred to FDP collection tube for FDPs estimation. The results and data obtained were subjected to statistical analysis by using chi-square test (X^2) and level of significance was done.

Results:
The results and level of significance of these groups are given in tables 1 and 2

<table>
<thead>
<tr>
<th>FDPsµg/ml</th>
<th>Group-I Breast Cancer Patients</th>
<th>Group-II (Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;5</td>
<td>07 (14%)</td>
<td>25</td>
</tr>
<tr>
<td>&gt;5&lt;40</td>
<td>15 (30%)</td>
<td>-</td>
</tr>
<tr>
<td>≥40</td>
<td>28 (56%)</td>
<td>-</td>
</tr>
<tr>
<td>Total</td>
<td>50</td>
<td>25</td>
</tr>
</tbody>
</table>

Statistical analysis: II Vs I P<0.01(HS)
A Comparative Study of FDPs and D-dimers in Patients with Breast Cancer

Table 2: D-dimers in Control Group (II) and subjects with Breast Cancer (I)

<table>
<thead>
<tr>
<th>D-dimer (ng/ml)</th>
<th>Group I (Subjects with ca breast)</th>
<th>Group II (Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;250</td>
<td>01 (02%)</td>
<td>25</td>
</tr>
<tr>
<td>250 – 500</td>
<td>29 (58%)</td>
<td>-</td>
</tr>
<tr>
<td>500 – 1000</td>
<td>12 (24%)</td>
<td>-</td>
</tr>
<tr>
<td>1000 – 2000</td>
<td>08 (16%)</td>
<td>-</td>
</tr>
<tr>
<td>Total Subjects</td>
<td>50</td>
<td>25</td>
</tr>
</tbody>
</table>

Statistical Analysis II Vs I P < 0.01 (Highly significant)

Discussion:

Fibrinogen Degradation Products (FDPs): FDPs were found to be significantly increased (p< 0.01) in patients of breast cancer when compared with control group. These findings are consistent with the results of many investigators, including Gordon et al (1975) 12, Francis et al 1994 5 and Falanga & Rickles (1999) 5.

D-dimers: D-dimers were found to be significantly increased (p<0.01) in patients with breast cancer when compared with controls. These findings are consistent with the results of Falanga & Rickles (1999) 5 Gordon et al (1975) 10 and Rickles et al (1992) 8.

References: